bioAffinity reports CyPath Lung sales growth and Philips veteran screening collaboration

bioAffinity Technologies filed an 8-K on June 30, 2026, disclosing its first quarterly company newsletter. The newsletter, released on June 30, 2026, provides an overview of certain recent developments at the company.¹

The company reported continued growth in orders for its noninvasive lung cancer test. CyPath Lung unit sales in April increased nearly 300% compared to April 2025.¹ The count of physician offices and clinics placing orders for the test rose 69% between the first quarters of 2025 and 2026.¹ The company attributed this to expanding the number of ordering physician sites, increasing education among pulmonologists, family practice doctors, and oncologists, and building CyPath Lung into clinical workflows for assessing lung cancer risk and managing nodules.¹

bioAffinity also announced a new collaboration. The company is working with Philips to strengthen screening initiatives aimed at U.S. veterans facing risk of lung diseases, including cancer, combining mobile CT scanning, the CyPath Lung test, and imaging software from 4DMedical.¹ A webinar on the initiative, hosted by the National Association of Veterans Research and Education Foundations, is scheduled for July 21 at 6:00 pm ET, covering early-stage lung disease detection and risk stratification for veterans eligible under the PACT Act.¹

On the research side, the company disclosed preclinical findings related to skin cancer. bioAffinity reported preclinical data showing that blocking certain cell surface receptors with its proprietary siRNA approach can destroy squamous skin cancer cells or slow their growth, without harming normal skin cells.¹ The company is also pursuing companion diagnostics work: a pilot study with Brooke Army Medical Center is underway to evaluate tests designed to measure lung inflammation type to guide drug selection for asthma and COPD patients.¹